BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a decade. Standard-of-care treatment relies on Cisplatin plus Pemetrexed chemotherapy. Here, we tested a suite of BH3-mimetic drugs targeting BC...

Descripción completa

Detalles Bibliográficos
Autores principales: Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603509/
https://www.ncbi.nlm.nih.gov/pubmed/33298868
http://dx.doi.org/10.1038/s41420-020-00348-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603509/
https://www.ncbi.nlm.nih.gov/pubmed/33298868
http://dx.doi.org/10.1038/s41420-020-00348-1

Ejemplares similares